Skip to main content

You must be a logged-in member of UHMS or a subscriber to the UHMS Journal in order to download the articles listed within these pages. If you are a member or subscriber, please log in using the Log In button above. If you would like to purchase a membership or a subscription, use the buttons below.

Join the UHMS
Purchase a Subscription

Search UHM/UBR

Adjunctive hyperbaric oxygen treatment for idiopathic sudden sensorineural hearing loss

Introduction: This study aims to evaluate the hearing gain efficacy from adjunctive hyperbaric oxygen (HBO2) treatment in patients with idiopathic sudden sensorineural hearing loss (ISSHL).

Materials and Methods: A retrospective analysis of chart reviews was performed on patients with ISSHL between January 2013 through December 2015. All patients were referred to us from our ENT Department for adjunctive hyperbaric oxygen treatment. The results were assessed through pure-tone audiometry (PTA) data change (hearing gain), both before and after HBO2 treatment. Age, gender, affected ear side, HBO2 treatment sessions, both before and after HBO2 treatment PTA were all recorded.

Results: Ninety-three (93) patients with ISSHL were included in the study. The average hearing gain in this study was 17.9 dB (p=0.001), where a total of 46 (49.46%) patients showed an improvement (hearing gain ≥10 dB) in response to HBO2 treatment (p=0.002). Patients with the poorest initial severity of hearing loss who displayed a greater degree of hearing improvement after HBO2 treatment were male and in the 40- to 59-year-old age group.

Conclusion: This study found that adjunctive hyperbaric oxygen treatment was efficacious for patients with idiopathic sudden sensorineural hearing loss. The total average hearing gain was recorded to be 17.9 dB.

DOI: 10.22462/1.2.2017.10